Published in Can J Cardiol on November 01, 2010
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2004) 3.47
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol (2009) 2.85
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol (2007) 2.66
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol (2009) 2.10
Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation (2005) 1.67
Peri-procedural myocardial injury: 2005 update. Eur Heart J (2005) 1.67
Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol (2009) 1.12
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol (2007) 1.10
Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology (2010) 1.02
The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol (2008) 0.97
Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation (2003) 0.86
Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J (Engl) (2009) 0.82
Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. J Am Coll Cardiol (2009) 0.81
Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol (2010) 0.80
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (2006) 2.98
Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation (2002) 2.97
Differences in medical care and disease outcomes among black and white women with heart disease. Circulation (2003) 2.16
Acute aortic dissection related to crack cocaine. Circulation (2002) 1.97
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet (2009) 1.87
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation (2012) 1.76
Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation (2004) 1.68
Cardiac arrest in patients who smoke crack cocaine. Am J Cardiol (2007) 1.49
Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later. Am J Cardiol (2002) 1.39
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation (2007) 1.10
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol (2009) 1.04
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement (2008) 1.01
Retracted Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol (2011) 0.99
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary. Circulation (2004) 0.98
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol (2007) 0.97
Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol (2011) 0.96
Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials. Prog Cardiovasc Dis (2005) 0.96
Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J (2009) 0.93
Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria? J Womens Health (Larchmt) (2008) 0.92
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol (2008) 0.89
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther (2012) 0.88
Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis (2004) 0.88
Racial differences of lipoprotein subclass distributions in postmenopausal women. Ethn Dis (2008) 0.87
What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation (2005) 0.87
Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Curr Med Res Opin (2010) 0.86
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis (2012) 0.85
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet (2011) 0.84
Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation (2004) 0.83
Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis (2004) 0.83
Tobacco smoke and cardiovascular risk: a call for continued efforts to reduce exposure. Curr Opin Cardiol (2011) 0.82
Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study). Am J Cardiol (2005) 0.82
Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail (2006) 0.81
Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction </=45 years of age. Am J Cardiol (2004) 0.81
The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis (2002) 0.80
Retracted Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease. Am Heart J (2012) 0.80
Papering over the cracks: meta-analysis to define the role of percutaneous coronary intervention in patients with stable angina. Can J Cardiol (2012) 0.79
Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics (2010) 0.78
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol (2015) 0.78
Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2). Am J Cardiol (2011) 0.76
Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog Cardiovasc Dis (2003) 0.76
Hemodynamic and arrhythmogenic effects of cocaine in hypertensive individuals. J Clin Hypertens (Greenwich) (2011) 0.76
A winter's tale: report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. Can J Cardiol (2009) 0.75
The SPARCL study: extending the indications of statin therapy for stroke? Nat Clin Pract Cardiovasc Med (2007) 0.75
Reply: To PMID 23219296. J Am Coll Cardiol (2013) 0.75
Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better? J Am Coll Cardiol (2015) 0.75
Estrogen therapy for unstable angina: another bump for the bandwagon. J Am Coll Cardiol (2002) 0.75
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol (2012) 0.75
Preventing and treating stroke and transient ischemic attack. Am J Cardiol (2007) 0.75
On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study. Eur J Clin Invest (2010) 0.75
Comparison of lipid profiles and attainment of lipid goals in patients <65 years versus patients ≥65 years (from the Lipid Treatment Assessment Project [L-TAP] 2). Am J Cardiol (2012) 0.75
Heart failure in persons living with HIV infection. Curr Opin HIV AIDS (2017) 0.75
Statin therapy in acute coronary syndrome. Am J Cardiol (2006) 0.75